bioRxiv Science⌕ Search

Biology subjects

Trapani, J.

Publications and source records attributed to Trapani, J..

2 recordsLinked to original sources

Phase-Separated RNA Condensates Govern Cas13 Target Accessibility and Cleavage

RNA-guided CRISPR-Cas13 nucleases must efficiently locate and target specific transcripts amidst the millions of other RNA molecules that are spatially regulated in the cell. Yet the mechanisms by which Cas13 finds its targets within this crowded, compartmentalized environment remain elusive. Here, we show that diverse Cas13 orthologs assemble into distinct cytoplasmic granules in a crRNA-concentration dependent manner. These granules exhibit hallmark features of phase-separated condensates, displaying liquid-like viscoelasticity and dynamic molecular exchange with the cytoplasm, as demonstrated by FRAP analysis in both human and bacterial cells. Molecular profiling revealed that Cas13 co-localizes with polyadenylated RNAs and noncoding RNAs within condensates that display markers of canonical RNA granules. Biochemical purification coupled with RNA sequencing shows Cas13 associated with thousands of transcripts within condensates, likely mediated by electrostatic interactions with its positively charged surface. Notably, Cas13 retains catalytic activity within these condensates, efficiently cleaving co-localized targets, whereas RNA species excluded from the condensates remain largely protected from Cas13 cleavage. This data indicates that condensate-based spatial organization facilitates efficient sampling and binding of diverse RNA targets by concentrating Cas13 and its substrates within a confined, liquid-like compartment. Together, our findings uncover a conserved spatial mechanism regulating Cas13 activity across bacterial and mammalian cells, where localization within RNA dense granules governs Cas13 activity in cells.

molecular biology↗

Genome-wide CRISPR screens reveal APR-246 (Eprenetapopt) triggers ferroptosis and inhibits iron-sulfur cluster biogenesis

The mechanisms by which cells respond and adapt to oxidative stress are largely unknown but are key to developing a rationale for cancer therapies that target antioxidant pathways. APR-246 is a mutant-p53 targeted therapeutic currently under clinical investigation in myeloid dysplastic syndrome (MDS) and acute myeloid leukemia1. Whilst the mechanism of action of APR-246 is thought to be reactivation of wild-type p53 activity through covalent modification of cysteine residues in the core domain of mutant-p53 protein2,3, here we report that the anti-neoplastic capacity of APR-246 lies predominantly in the conjugation of free cysteine. Genome-wide CRISPR perturbation screening, metabolite profiling and proteomics in response to APR-246 treatment in mutant-p53 cancer cells highlighted the role of GSH and mitochondrial metabolism in determining APR-246 efficacy. APR-246 sensitivity was increased through loss of key enzymes in mitochondrial one-carbon metabolism, SHMT2 and MTHFD1L, due to diminished glycine supply for de novo GSH synthesis. Critically, we show that APR-246 induces iron-dependent, apoptotic machinery-independent cell death, ferroptosis. Whole-cell proteomics analyses indicated an upregulation of proteins involved in iron-sulfur cluster biogenesis (eg. FDX1). GSH, acetyl-CoA and NADH levels were also depleted in APR-246 treated cells. Importantly, we found that APR-246 inhibits iron-sulfur cluster biogenesis in the mitochondria of cancer cells through cysteine conjugation. This work not only details novel determinants of APR-246 activity in cancer cells, but also provides a clinical roadmap for targeting antioxidant pathways in tumours - beyond targeting mutant-p53 tumours. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/398867v1_ufig1.gif" ALT="Figure 1"> View larger version (16K): org.highwire.dtl.DTLVardef@11155f8org.highwire.dtl.DTLVardef@1231cb7org.highwire.dtl.DTLVardef@324881org.highwire.dtl.DTLVardef@136146f_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗